Bora Pharmaceuticals - Public Comps and Valuation Multiples

Bora Pharmaceuticals Overview

About Bora Pharmaceuticals

Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Commercial sales segment, Contract Development & Manufacturing Organization segment, and Other segment. The majority of revenue is derived from the Commercial sales segment. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.

Founded

2007

HQ

Employees

163

Website

bora-corp.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
Contract Research & Manufacturing
BioTech

Financials

LTM Revenue $631M

LTM EBITDA $189M

EV

$2.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Bora Pharmaceuticals Financials

As of November 2025, Bora Pharmaceuticals reported last 12-month revenue of $631M and EBITDA of $189M.

In the same period, Bora Pharmaceuticals generated $273M in LTM gross profit and $126M in net income.

See Bora Pharmaceuticals valuation multiples based on analyst estimates

Bora Pharmaceuticals P&L

In the most recent fiscal year, Bora Pharmaceuticals reported revenue of $613M and EBITDA of $206M.

Bora Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Bora Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$631M	XXX	$613M	XXX	XXX	XXX
Gross Profit	$273M	XXX	$245M	XXX	XXX	XXX
Gross Margin	43%	XXX	40%	XXX	XXX	XXX
EBITDA	$189M	XXX	$206M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	34%	XXX	XXX	XXX
EBIT	$130M	XXX	$108M	XXX	XXX	XXX
EBIT Margin	21%	XXX	18%	XXX	XXX	XXX
Net Profit	$126M	XXX	$125M	XXX	XXX	XXX
Net Margin	20%	XXX	20%	XXX	XXX	XXX
Net Debt	XXX	XXX	$391M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Bora Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $631M. EBITDA for the last twelve months was $189M. In the most recent fiscal year, Bora Pharmaceuticals achieved $613M in revenue and $206M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$631M	Analyst estimates available to subscribers	$613M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$273M	Analyst estimates available to subscribers	$245M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	43.2% gross margin	Analyst estimates available to subscribers	40.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$189M	Analyst estimates available to subscribers	$206M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	29.9% EBITDA margin	Analyst estimates available to subscribers	33.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$130M	Analyst estimates available to subscribers	$108M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	20.6% EBIT margin	Analyst estimates available to subscribers	17.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$126M	Analyst estimates available to subscribers	$125M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	20.0% net profit margin	Analyst estimates available to subscribers	20.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$391M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Bora Pharmaceuticals

This financial data table provides comprehensive performance metrics for Bora Pharmaceuticals, a company based in Taiwan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Bora Pharmaceuticals generated $631M in revenue over the last twelve months.
The company achieved $189M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $273M.
Net income over the last twelve months reached $126M.

Fiscal Year Performance

In the most recent fiscal year, Bora Pharmaceuticals reported $613M in total revenue.
Fiscal year EBITDA was $206M.
The company maintained a gross profit margin of 40.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 33.6%.
Net profit margin reached 20.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Bora Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Bora Pharmaceuticals Stock Performance

Bora Pharmaceuticals has current market cap of TWD 65.7B (or $2.1B), and EV of TWD 80.8B (or $2.6B).

Market Cap Evolution

Bora Pharmaceuticals Stock Data

As of December 3, 2025, Bora Pharmaceuticals's stock price is TWD 529 (or $17).

See Bora Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.6B	$2.1B	XXX	XXX	XXX	XXX	$1.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Bora Pharmaceuticals Valuation Multiples

Bora Pharmaceuticals's trades at 4.2x EV/Revenue multiple, and 12.5x EV/EBITDA.

See valuation multiples for Bora Pharmaceuticals and 15K+ public comps

Bora Pharmaceuticals Financial Valuation Multiples

As of December 3, 2025, Bora Pharmaceuticals has market cap of $2.1B and EV of $2.6B.

Equity research analysts estimate Bora Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bora Pharmaceuticals has a P/E ratio of 16.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV (current)	$2.6B	XXX	$2.6B	XXX	XXX	XXX
EV/Revenue	4.1x	XXX	4.2x	XXX	XXX	XXX
EV/EBITDA	13.6x	XXX	12.5x	XXX	XXX	XXX
EV/EBIT	19.8x	XXX	23.9x	XXX	XXX	XXX
EV/Gross Profit	9.4x	XXX	n/a	XXX	XXX	XXX
P/E	16.6x	XXX	16.7x	XXX	XXX	XXX
EV/FCF	14.6x	XXX	275.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Bora Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Bora Pharmaceuticals Margins & Growth Rates

Bora Pharmaceuticals's last 12 month revenue growth is 25%

Bora Pharmaceuticals's revenue per employee in the last FY averaged $3.8M, while opex per employee averaged $0.8M for the same period.

Bora Pharmaceuticals's rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bora Pharmaceuticals's rule of X is 92% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Bora Pharmaceuticals and other 15K+ public comps

Bora Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	25%	XXX	14%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	34%	XXX	XXX	XXX
EBITDA Growth	34%	XXX	11%	XXX	XXX	XXX
Rule of 40	59%	XXX	58%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	92%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$3.8M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	22%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial